Latest News

Keep up to date with the latest news from Pilatus Biosciences.

News

December 15, 2025

Pilatus Biosciences Announces FDA Clearance of IND Application for PLT012, a First-in-Class Anti-CD36 Metabolic Checkpoint Antibody in Solid Tumors

October 30, 2025

Pilatus Biosciences to Present New Preclinical Data Highlighting PLT012’s Ability to Induce Durable Anti-Tumor Immunity Through Immunometabolic Reprogramming of the Tumor Microenvironment at SITC 2025 Annual Meeting

October 14, 2025

Pilatus Biosciences Announces Issuance of Foundational Global Patent Covering Novel CD36-Targeted Immunotherapy

August 13, 2025

Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in Hepatocellular Carcinoma

Upcoming Events

Currently, there are no scheduled upcoming events.